Display options
Cite
Plunkett C, Barkan AL. The care continuum in acromegaly: how patients, nurses, and physicians can collaborate for successful treatment experiences. Patient Prefer Adherence. 2015;9:1093-9doi: 10.2147/PPA.S84887.
Plunkett, C., & Barkan, A. L. (2015). The care continuum in acromegaly: how patients, nurses, and physicians can collaborate for successful treatment experiences. Patient preference and adherence, 91093-9. https://doi.org/10.2147/PPA.S84887
Plunkett, Cynthia, and Barkan, Ariel L. "The care continuum in acromegaly: how patients, nurses, and physicians can collaborate for successful treatment experiences." Patient preference and adherence vol. 9 (2015): 1093-9. doi: https://doi.org/10.2147/PPA.S84887
Plunkett C, Barkan AL. The care continuum in acromegaly: how patients, nurses, and physicians can collaborate for successful treatment experiences. Patient Prefer Adherence. 2015 Jul 30;9:1093-9. doi: 10.2147/PPA.S84887. eCollection 2015. PMID: 26251582; PMCID: PMC4524590.
Copy Download .nbib Format: NLM
Share it on

Patient Prefer Adherence. 2015 Jul 30;9:1093-9. doi: 10.2147/PPA.S84887. eCollection 2015.

The care continuum in acromegaly: how patients, nurses, and physicians can collaborate for successful treatment experiences.

Patient preference and adherence

Cynthia Plunkett, Ariel L Barkan

Affiliations

  1. Division of Endocrinology, University of Michigan Medical Center, Ann Arbor, MI, USA.

PMID: 26251582 PMCID: PMC4524590 DOI: 10.2147/PPA.S84887

Abstract

Patients with acromegaly (a condition of chronic growth hormone hypersecretion by a pituitary adenoma) often require pharmacological treatment. Somatostatin analogs (SSAs) such as pasireotide, lanreotide, and octreotide are frequently used as first-line medical therapy. As SSAs are delivered by regular subcutaneous or intramuscular injections, they can result in injection-related pain or anxiety and can be challenging to fit into patients' lifestyles. When combined with the prolonged, debilitating psychological complications associated with acromegaly, these administration challenges can negatively impact compliance, adherence, and quality of life. Proactively managing patients' expectations and providing appropriate, timely guidance are crucial for maximizing adherence, and ultimately, optimizing the treatment experience. As part of ongoing clinical research since 1997, our team at the University of Michigan has used SSAs to treat 30 patients with acromegaly. Based on our clinical experiences with multiple SSA administration regimens (long-acting intramuscular, long-acting deep subcutaneous, and twice-daily subcutaneous), we generated a dialog map that guides health care professionals through the many sensitive and complex patient communication issues surrounding this treatment process. Beginning with diagnosis, the dialog map includes discussion of treatment options, instruction on proper drug administration technique, and ensuring of appropriate follow-up care. At each step, we provide talking points that address the following: the patients' clinical situation; their geographic, economic, and psychological concerns; and their inclination to communicate with clinicians. We have found that involving patients, nurses, and physicians as equal partners in the treatment process optimizes treatment initiation, adherence, and persistence in acromegaly. By encouraging collaboration across the care continuum, this dialog map can facilitate identification of the treatment plan that is most likely to yield the best possible outcome.

Keywords: adherence; lanreotide; octreotide; pasireotide; somatostatin analogs

References

  1. Medscape J Med. 2008;10(9):225 - PubMed
  2. Mult Scler. 2005 Jun;11(3):322-7 - PubMed
  3. Endocr Pract. 2008 Oct;14 (7):846-55 - PubMed
  4. J Clin Endocrinol Metab. 2008 Jan;93(1):61-7 - PubMed
  5. Healthc (Amst). 2013 Dec;1(3-4):117-122 - PubMed
  6. Br J Cancer. 2001 Nov 2;85(9):1273-9 - PubMed
  7. J Clin Endocrinol Metab. 2008 Sep;93(9):3436-42 - PubMed
  8. Expert Opin Emerg Drugs. 2014 Mar;19(1):79-97 - PubMed
  9. J Clin Endocrinol Metab. 2001 Jun;86(6):2779-86 - PubMed
  10. Clin Endocrinol (Oxf). 2008 Oct;69(4):613-20 - PubMed
  11. Pituitary. 2011 Sep;14 (3):284-94 - PubMed
  12. J Neurosci Nurs. 2010 Oct;42(5 Suppl):S19-29 - PubMed
  13. Pituitary. 2013 Jun;16(2):245-50 - PubMed
  14. J Neurosci Nurs. 2010 Oct;42(5 Suppl):S10-8 - PubMed
  15. N Engl J Med. 2005 Aug 4;353(5):487-97 - PubMed
  16. Patient Prefer Adherence. 2012;6:871-85 - PubMed
  17. J Clin Endocrinol Metab. 2004 Feb;89(2):667-74 - PubMed
  18. Mult Scler. 2007 Nov;13(9):1146-52 - PubMed
  19. Patient Prefer Adherence. 2012;6:73-82 - PubMed
  20. Eur J Endocrinol. 2003 Jan;148(1):31-8 - PubMed
  21. J Clin Endocrinol Metab. 2014 Mar;99(3):791-9 - PubMed
  22. J Clin Endocrinol Metab. 2014 May;99(5):1825-33 - PubMed
  23. Expert Opin Investig Drugs. 2013 Aug;22(8):955-63 - PubMed
  24. Eur J Endocrinol. 2008 Aug;159(2):89-95 - PubMed
  25. BMC Public Health. 2012 Mar 08;12:167 - PubMed
  26. Pituitary. 2013 Sep;16(3):294-302 - PubMed
  27. Eur J Endocrinol. 2010 Jun;162(6):1035-42 - PubMed
  28. Pituitary. 2014 Feb;17 (1):13-21 - PubMed
  29. Med Care. 2009 Aug;47(8):826-34 - PubMed
  30. Milbank Q. 1996;74(4):511-44 - PubMed
  31. Int J Gen Med. 2013;6:31-8 - PubMed
  32. Eur J Endocrinol. 2002 May;146(5):707-16 - PubMed
  33. J Clin Endocrinol Metab. 2006 Jun;91(6):2112-8 - PubMed
  34. J Neurosci Nurs. 2007 Apr;39(2):89-101 - PubMed
  35. IDrugs. 2007 Dec;10(12):885-95 - PubMed
  36. Patient Prefer Adherence. 2014 Jan 09;8:53-62 - PubMed
  37. J R Soc Med. 2003 May;96(5):219-22 - PubMed
  38. Patient Prefer Adherence. 2013 Jul 29;7:709-18 - PubMed
  39. Ther Clin Risk Manag. 2005 Sep;1(3):189-99 - PubMed
  40. J Clin Endocrinol Metab. 2000 Sep;85(9):3132-40 - PubMed
  41. J Neurosci Nurs. 2003 Jun;35(3):163-70 - PubMed
  42. Clin Endocrinol (Oxf). 2008 Mar;68(3):343-9 - PubMed
  43. Clin Endocrinol (Oxf). 2006 Mar;64(3):342-51 - PubMed
  44. J Clin Pharm Ther. 2001 Oct;26(5):331-42 - PubMed
  45. J Neurosci Nurs. 2001 Oct;33(5):231-9 - PubMed
  46. Pituitary. 2010 Jun;13(2):115-22 - PubMed
  47. Clin Endocrinol (Oxf). 2009 Aug;71(2):237-45 - PubMed
  48. Med Care. 2004 Mar;42(3):200-9 - PubMed
  49. J Neurosci Nurs. 2006 Jun;38(3):167-71 - PubMed
  50. Eur J Endocrinol. 2011 Nov;165(5):713-21 - PubMed
  51. Clin Endocrinol (Oxf). 2007 Oct;67(4):512-9 - PubMed
  52. Nat Rev Endocrinol. 2011 May;7(5):291-300 - PubMed

Publication Types